Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741295 | 0.89 | HTR6 (0.53) | HTR6POLBCYP3A4RORCLMNA | |
| SCHEMBL6743416 | 0.89 | HTR6 (0.58) | HTR6POLBCYP3A4RORCKMT2A | |
| SCHEMBL6745742 | 0.86 | HTR6 (0.61) | HTR6POLBCYP3A4KMT2A | |
| SCHEMBL6744457 | 0.86 | HTR6 (0.76) | HTR6POLBCYP3A4RORCMAPT | |
| SCHEMBL7172960 | 0.84 | HTR6 (0.53) | HTR6POLBCYP3A4ALDH1A1 | |
| SCHEMBL3128669 | 0.84 | HTR6 (0.79) | HTR6 | |
| SCHEMBL7044429 | 0.84 | HTR6 (0.51) | HTR6POLBRORCLMNATDP1 | |
| SCHEMBL6747464 | 0.84 | HTR6 (0.79) | HTR6 | |
| Hydrochloric Acid SCHEMBL6833514 | 0.83 | HTR6 (0.78) | HTR6 | |
| SCHEMBL6742375 | 0.83 | HTR6 (0.76) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207866-A1 | Drugs useful for the treatment of diseases or disorders of the central nervous system. | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
| US-6586592-B2 | Labled isotopes of phenyl 4-(1,4-diazepin-1-yl)-2-amino phenyl sulfone derivatives used in nuclear magnetic resonance imaging and positron emission tomography | PHARMACIA & UPJOHN COMPANY | 2003-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207866-A1 | Drugs useful for the treatment of diseases or disorders of the central nervous system. | PMP22, NLN, INA | HTR6 221/4885POLB 4200/4885CYP3A4 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.